Clever Leaves, a world cannabis firm with its most important operations in Colombia, stated Thursday it obtained EU-Good Manufacturing Practice certification “to produce Active Pharmaceutical Ingredients (API), semi-finished and finished cannabis products for medical purposes” in its Colombian services.
The certification is “expected to broaden Clever Leaves’ ability to serve international markets,” in response to the information launch.
EU-GMP is an important requirement to exporting medical marijuana – notably extracts – for business and medicinal functions to markets in the European Union.
“Any manufacturer of medicines intended for the EU market, no matter where in the world it is located, must comply with GMP,” the European Medicines Agency web site stipulates.
A Clever Leaves spokesperson advised Marijuana Business Daily that the Croatian Agency for Medicinal Products and Medical Devices inspected the corporate’s services in Colombia in January, issuing the certificates – verified by MJBizDaily – this week.
Only a handful of cannabis services in the world have EU-GMP certification to fabricate extracts.
Marijuana Business Daily isn’t conscious of another cannabis producer that has publicly introduced acquiring EU-GMP certification for a Latin American facility, and no cannabis facility on the continent could be discovered in the publicly out there official EudraGMDP database of the European Union.
While exports of high-THC medical flower to the European Union with out EU-GMP certification are doable underneath sure circumstances, Colombia doesn’t enable the exportation of flower for business functions.
This leaves Colombian producers little room to maneuver apart from acquiring the EU certification in the event that they need to export medicinal extracts manufactured from Colombia to the EU.
Clever Leaves, in the meantime, is aiming to checklist on the Nasdaq inventory market.